WuXi XDC Congratulates EDDC on FDA Clearance of IND Application for First Made-in-Singapore Antibody-Drug Conjugate

SHANGHAI, March 8, 2023 /PRNewswire/ — WuXi XDC (“XDC”), a leading global CRDMO company dedicated to end-to-end bioconjugate services, congratulates its partner, the Experimental Drug Development Centre (EDDC), Singapore’s national drug discovery and development platform hosted by the…